Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples